Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Also known as: Diffuse Large B-Cell Lymphoma-Refractory / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / B Cell Refractory Diffuse Large B-Cell Lymphoma / Diffuse Large B Cell Lymphoma Refractory / Refractory Diffuse Large B-Cell Lymphoma / Diffuse Large B-cell Lymphoma Refractory / Refractory Diffuse Large B Cell Lymphoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB13915 | Axicabtagene ciloleucel | A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. |
| DB16672 | Epcoritamab | A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. |
| DB16371 | Glofitamab | A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. |
| DB00480 | Lenalidomide | A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. |
| DB16582 | Lisocabtagene maraleucel | A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas. |
| DB16222 | Loncastuximab tesirine | An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas. |
| DB13881 | Tisagenlecleucel | A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. |